Radiation Oncology Institute launched with $5 million ASTRO grant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 9
Volume 17
Issue 9

FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.

FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.

 

Theodore S. Lawrence, MD, PhD, from the University of Michigan in Ann Arbor and Colleen A. Lawton, MD, from the Medical College of Wisconsin in Milwaukee will lead the endowment campaign. Their goal is to raise $10 million in capital to build the infrastructure of the new ROI, according to ASTRO.

 

Once ROI is functional, it will serve as the chief philanthropic partner to ASTRO. Possible ROI programs include supporting research studies or impact analyses of new and existing treatment options; conducting outcomes studies on the efficacy and cost/ benefit of radiation therapy; and publishing radiation oncology-related trend data. ROI also will build a database of workforce and practice structures.

 

From ASTRO’s $5 million investment, $1 million will be used for an endowment and $1 million for initial seed funding.

Recent Videos
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content